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Metabolic syndromeAbstract Chronic obstructive pulmonary disease (COPD) has extrapulmonary effects that seem to
be related with systemic inflammation. The relationship between metabolic syndrome which is an
important determinant of systemic inflammation in the general population and COPD is still not
clear.
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COPD is a growing cause of morbidity and mortality world-
wide, and will be the third leading cause of death by 2020
COPD is defined as a preventable and treatable disease with
significant extra pulmonary effects that may contribute to its
severity in individual patients [1].
Chronic obstructive pulmonary disease (COPD) is a state
characterized by airflow limitation that is not fully reversible.
The airflow limitation is usually both progressive and associ-
ated with an abnormal inflammatory response of the lungs
to noxious particles or gases [2].
The term chronic systemic inflammatory syndrome has
been proposed to take account of the inflammatory nature
common to chronic obstructive pulmonary disease (COPD)
and its comorbid conditions [3]. One of these possible comor-
bid conditions is metabolic syndrome, an aggregate of interre-lated cardio metabolic risk factors, comprising glucose
intolerance, abdominal obesity, dyslipidemia and hyperten-
sion, which are associated with an increased risk of cardiovas-
cular disease and type 2 diabetes.
Approximately 40–50% of individuals >60 years of age in
industrialized countries meet the criteria for metabolic syn-
drome. The metabolic syndrome represents a cluster of risk
factors (abdominal obesity, atherogenic dyslipidemia, hyper-
tension and insulin resistance) that predispose affected patients
to systemic inflammation, cardiovascular disease and physical
inactivity [4].
Aim of work
Aim of the work is to detect incidence of metabolic syndrome
in COPD patients and its correlation with severity of COPD.
Patients and methods
70 Stable COPD patients and 20 control subjects were
included in the study. The severity level in patients with COPD
Table 2 Comparative statistical analysis between patients and
control according to metabolic parameters.
Patient
Mean ± SD
Control
Mean ± SD
p-Value Sig
Waist 92.9 ± 16.1 9404 ± 10.2 0.707 NS
FBS 100.3 ± 12.5 90.4 ± 14.6 0.022 S
BP 118.4 ± 17.5 113.3 ± 13.1 0.248 NS
TG 181 ± 97.2 101.6 ± 37.7 0.001 HS
HDL 47.1 ± 18.6 58 ± 7.4 0.012 S
Table 3 Percent of each content diagnosing metabolic
syndrome in COPD patients and control and its statistical
comparative analysis.
Patient% Control% p-Value Sig
Waist 21 (30) 5 (25) 0.665 NS
FBS 40 (57.1) 6 (30) 0.042 S
BP 22 (31.4) 3 (15) 0.171 NS
TG 36 (51.4) 1 (5) 0.001 HS
HDL 25 (35.7) 1 (5) 0.009 HS
Table 4 Incidence of metabolic syndrome in COPD patients
and control.
Metabolic Non-metabolic Total
Patient no% 23 (32.9) 47 (67.1) 70 (100)
Control no% 1 (5) 19 (95) 20 (100)
Table 5 Incidence of metabolic syndrome in different severity
of COPD patients.
Severity Metabolic no% Non-metabolic no%
Mild 1 (11.1) 8 (88.9)
Moderate 8 (34.8) 15 (65.2)
Severe 5 (25) 15 (75)
Very severe 9 (50) 9 (50)
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Chronic Obstructive Lung Disease) criteria. American Heart
Association/National Heart, Lung, and Blood Institute
(AHA/NHLBI) definition was used in the diagnosis of meta-
bolic syndrome. We measured the characteristics of the meta-
bolic syndrome (waist circumference, blood pressure, fasting
blood glucose, serum triglycerides and HDL).
Results
The results are provided in Tables 1–6.
Discussion
The present study was to detect incidence of metabolic syn-
drome and its components. This study included 90 individuals:
70 male stable COPD patients and 20 male healthy control
group. COPD patients were chosen from the chest department
and outpatient clinic of Beni Sweif University hospital.
Healthy control group was selected at random. All COPD
patients and healthy control group are cigarette smokers with
a higher smoking index for COPD patients than the control
group.
Comparing each metabolic parameter between COPD
patients and control group showed higher serum triglycerides
in COPD than the control group (mean 181 vs 101.6) with sta-
tistical significance (p value = 0.001). Also, fasting blood
sugar was higher in COPD than control group (mean 100.3
vs 90.4) with statistical significance (p value = 0.022) but
HDL was lower in COPD than the control group (47.1 vs
58) with statistical significance (p value = 0.040).
However, waist circumference and blood pressure both
were higher in COPD than the control group (92.9 vs 94.4),
(systolic BP 118.4 vs 113.5) but not statistically significant (p
value = 0.707, 0.218 respectively) (Table 2).
Our study, found a high significance between COPD and
control group regarding hyperglycemia that agrees with Akpi-
nar. In contrast to the present study, it was found that abdom-
inal obesity and hypertension were significantly high in COPD
than the control group [5].
This disagrees with Waqar A. who found that HDL con-
centrations in COPD patients were significantly higher than
the controls [6].
Then percent of each component of the metabolic syn-
drome was estimated in COPD patients and control group.Table 1 Demographic, functional parameters of syndrome of
COPD patients (70) and control (20).
Items Patient (n= 70)
Mean ± SD
Control (n= 20)
Mean ± SD
Age 56.6 ± 9.02 42.7 ± 2.5
Sex All are males All are males
Smoking index 420 ± 12.2 110 ± 10.5
FEV1/FVE 53.1 ± 10.9 79.1 ± 5.0
Waist cir 92.9 ± 16.1 94.4 ± 10.2
FBS 100.3 ± 12.5 90.4 ± 14.6
BP 123.4 ± 17.5 113.5 ± 13.1
TG 181 ± 79.2 101.6 ± 37.7
HDL 49.1 ± 18.6 58.0 ± 7.4In COPD patients, abdominal obesity was represented in
30%, elevated triglyceride levels in 51.4%, low HDL-C levels
in 35.7%, elevated fasting glucose levels in 57.1%, and raised
blood pressure in 31.4%.
Control participants showed 25% abdominal obesity, 5%
elevated triglycerides, 5% had low HDL-C levels, 30% ele-
vated fasting glucose levels, and 15% raised blood pressure
(Table 3). So, in COPD patients, the highest percent was
hyperglycemia followed by elevated triglycerides then HDL
(57.1%, 51.4%, 35.7%) respectively but abdominal obesity
and hypertension were of lowest incidence (30%, 31.4%
respectively).
On studying incidence in other studies versus Akpinar
found a higher incidence of abdominal obesity (52.2% vs
30%), and higher incidence of hypertension (77.2% vs
31.4%) but as regards incidence of hyperglycemia they found
the incidence lower than our incidence (46.7% vs 57.1%) [5].
Table 6 Comparison between COPD patients with metabolic
syndrome, without metabolic syndrome and control group
according to function and metabolic parameters.
Metabolic
syndrome
Without
Metabolic
syndrome
Control p-
Value
Sig
FEV1/
FVC
51.3 ± 9.7 54.1 ± 11.5 79.1 ± 5 0.001 HS
FEV1 42.1 ± 20.1 51.0 ± 21.2 83.7 ± 6.4 0.001 HS
Waist 10.24 ± 17.9 88.3 ± 12.9 94.4 ± 10.2 0.001 HS
FBS 115.3 ± 26.8 92.9 ± 14.6 95.4 ± 14.6 0.001 HS
BP 129.8 ± 99.8 120.2 ± 16.2 113.5 ± 13.1 0.005 HS
TG 226.7 ± 99.8 158 ± 88.7 101.6 ± 37.7 0.001 HS
HDL 40.7 ± 12.9 53.2 ± 19.6 58 ± 7.4 0.001 HS
BMI 29.2 ± 6.8 22.5 ± 4.6 23.4 ± 2.9 0.001 HS
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obesity (61% vs 30%), and higher incidence of hypertension
(77.2% vs 31.4%) but as regards incidence of hyperglycemia
they found the incidence lower than our incidence (46.7% vs
57.1%) [7].
Lam K.-B.H. found that there was higher incidence of
raised blood pressure (56.7% vs 31.4%) but there was lower
incidence of elevated triglyceride levels (29.6% vs 51.4%),
lower incidence of elevated fasting glucose levels (34.3% vs
57.1%) and decreased HDL-C levels (15.9% vs 35.7%). As
regards incidence of abdominal obesity, more or less approxi-
mately our incidence (34.1% vs 30%) [8].
Walters found that hypertension was highly prevalent
across COPD patients (70%) [9]. Also, Barr R.G. found a
hypertension frequency of 55% in patients with COPD. In
contrast, the incidence of hypertension in the present study
was low (31.4%) [10].
In the present study, estimating the incidence of metabolic
syndrome was based on the American Heart Association/
National Heart, Lung, and Blood Institute (AHA/NHLBI)
definition which was satisfied if at least three of the five criteria
of metabolic syndrome were met.
The incidence of metabolic syndrome in this study was
32.9% in COPD patients (No = 23 patients) and 5% in the
control group (No = 1 patients). So, about one third of
COPD patients have metabolic syndrome (Table 4).
The incidence of metabolic syndrome in the present study is
higher than K.-B.H. Lam who found that the prevalence of
metabolic syndrome was 22.6% in COPD patients and
19.8% in the control group. The study was done in Guangzhou
and included patients (never smokers 76.3%, former smokers
12.5%, and current smokers 11.2%) [8].
The incidence of metabolic syndrome in the present study
was higher than Lam study who showed that smoking has
been suggested as one of the major causes of systemic inflam-
mation in association with COPD and metabolic syndrome [8].
The higher frequency of smokers in the present study com-
pared to Lam K.-B.H. may have contributed to the higher
prevalence of metabolic syndrome in the present study (all
COPD patients are smokers: smoking index 420 ± 12.2),
who found that the prevalence of metabolic syndrome was
15% in COPD patients. The study was done in Paris andincluded patients (never smokers 47.0%, former smokers
21.2%, and current smokers 31.8%) [8].
Given that smoking has been suggested as one of the major
causes of systemic inflammation in association with COPD
and metabolic syndrome, the higher frequency of smokers in
the present study was compared to the above studies and
may have contributed to the higher prevalence of metabolic
syndrome in the present study (all COPD patients are smokers:
smoking index 420 ± 12.2).
Park B.H. found that the prevalence of metabolic syn-
drome, based on the NCEP-ATP III, was significantly higher
in COPD subjects compared with non-COPD subjects in both
sexes (33.0% vs 22.2% in men and 48.5% vs 29.6% in women).
So, the incidence of metabolic syndrome in male COPD
patients in their study more or less approximates incidence in
the present study [11].
Incidence of metabolic syndrome in different levels of sever-
ity of COPD patients was (11.1%) in mild COPD, (34.8%) in
moderate, (25%) in severe and (50%) very severe cases
(Table 5). Incidence of metabolic syndrome was higher in very
severe and moderate COPD patients but less in mild and severe
cases. So, incidence of metabolic syndrome in the present study
despite being highest in very severe cases, is less in severe than
moderate cases. So, incidence of metabolic syndrome is not
related to severity of COPD. It may increase with any stage
of COPD.
This agrees with Akpinar who found that the distribution
of the prevalence of MetS between GOLD stages I–IV were
as follows; 38.5%, 52.8%, 30% and 33.3% respectively [5].
This agrees with Waiters who observed a slightly lower fre-
quency of the metabolic syndrome in patients with severe to
very severe COPD. This observation might be best explained
by weight loss, which frequently occurs in patients who are
in the later stages of the disease [9].
K.-B.H. Lam observed that the risk of metabolic syndrome
increases with increasing severity of obstruction. However,
there is controversy regarding incidence in severe cases that
have less incidence of metabolic syndrome [8].
Correlation between severity of COPD (FEV1) and param-
eters of metabolic syndrome was done by Pearson (r) correla-
tion. This study showed inverse (negative) relation between
severity of COPD (FEV1) and parameters of metabolic syn-
drome except HDL which showed linear (positive) relation
with FEV1 (Table 6).
Correlation was significant for fasting blood glucose
(r= 0.4, p value = 0.038), triglycerides (r = 0.3, p value
0.047), HDL (r = 0.3, p value = 0.029). Tricia M. who found
that fasting glucose level was not related to Lung function.
This disagrees with the present study. However, Plasma glu-
cose level 2 h postprandial was inversely related to forced expi-
ratory volume in 1 s (FEV1), with a difference of _144.7 ml
(95% confidence interval: _231.9, _57.4) [12].
When comparing COPD patients with metabolic syndrome
and COPD patients without metabolic syndrome according to
functional and metabolic parameters, we found a statistically
significant difference regarding metabolic parameters but no
statistical significance regarding functional parameters (both
groups are COPD patients).
Stanciu S. noted that between the COPD patients with
metabolic syndrome and COPD patients without metabolic
syndrome, both functional lung parameters, represented
596 N.M. Ameen et al.mainly by FEV1 and the 6 min test, and metabolic parameters
show statistical significance [13].
Conclusion
The study showed that the frequency of metabolic syndrome
was higher in stable COPD (32.9%) patients than control sub-
jects (5%).
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